Collection episode 01 · 2:00 · English
Peptides in 2TM · Semax
Origins, history and human evidence
Meet the Moscow teams behind Semax, follow its development and 1994 medical registration, and explore its molecular design, stroke research, and the limits of the human evidence.
English narration with optional English captions. Caption timing is recognition-assisted. Translated subtitles are not yet available for this episode.
Published . Sources checked: October 16–17, 2026.
Behind the film: references & context
Origins and developers
Semax opens our brain, pain, and neuropeptides collection. Its story begins in Moscow, in the Soviet Union. Teams at Moscow State University and the Institute of Molecular Genetics worked under Igor Ashmarin and Nikolai Myasoedov. The manufacturer's history dates development to nineteen eighty and synthesis to nineteen eighty-five. [6][8][9][10]
History of use
Russia registered Semax for medical use in December nineteen ninety-four. That gives it more than thirty years of medical history by twenty twenty-six. [7]
Molecular design and mechanism
Semax contains seven amino acids. Four come from a fragment of ACTH, a natural hormone. Three more complete the molecule. In rats with interrupted brain blood flow, researchers found changes in genes linked to inflammation and nerve communication. Those findings suggest mechanisms, not clinical benefits in people. [1][2]
Human evidence
A nineteen ninety-seven stroke report compared thirty given Semax plus care with eighty receiving conventional care. Its authors reported better neurological recovery. The English abstract does not specify randomization or blinding. Stroke recovery and improving focus in healthy people are different questions. The preparation, population, and outcome matter. [3]
Limitations and safety
The FDA's twenty twenty-six compounding review raised concerns about product characterization, impurities, and possible immune reactions. [4][5]
Takeaway
A long history is part of the story. Careful human testing helps establish what the evidence supports. [3][4][7]
Original sources and source access
- FDA GSRS — Semax molecular identity
UNII I5FAL2585H; substance identity does not establish effectiveness.
- Filippenkov et al. (2020) — Rat cerebral ischemia–reperfusion study
Genes; PMID 32580520. Gene-expression findings in rats concern possible mechanisms, not clinical benefit in people.
- Gusev et al. (1997) — Semax in acute ischemic stroke
English abstract accessed; full Russian article not verified. The abstract does not specify randomization or blinding in the comparison of 30 Semax recipients with 80 conventional-care recipients.
- FDA (2026) — Pharmacy Compounding Advisory Committee staff briefing
Dated staff briefing for July 23–24, 2026. Product characterization, impurities, and possible immune reactions are discussed. This is not a final committee decision or current legal ruling.
- FDA — Understanding the risks of compounded drugs
Explains compounding risks and the distinction from approval.
- Semax manufacturer — Development chronology
Attributed manufacturer history: project start in 1980 and synthesis in 1985. These are distinct milestones.
- Russian Ministry — Order No. 294, December 20, 1994
Primary order reproduced by Jurbase, including Semax and its 0.1% preparation. A registration milestone does not document uninterrupted use by a defined patient group.
- Moscow State University — Igor Petrovich Ashmarin
Institutional biography supporting the developer attribution.
- Russian Academy of Sciences — Nikolai Fyodorovich Myasoedov
Institutional biography supporting the developer attribution.
- Ashmarin and colleagues (1997) — Fifteen years of design and study
Developers’ account; English abstract accessed.
Production notes
Four original AI-generated images each appear once, with the established series artwork at the opening and closing. The complete synthetic narration is retained at normal speed, including its natural pauses. Native history panels identify the developers, institutions, and dated milestones. Prompts, timing, captions, narration, and rendering files are included in the source package.
Read the English transcript
Semax opens our brain, pain, and neuropeptides collection. Its story begins in Moscow, in the Soviet Union.
Teams at Moscow State University and the Institute of Molecular Genetics worked under Igor Ashmarin and Nikolai Myasoedov. The manufacturer's history dates development to nineteen eighty and synthesis to nineteen eighty-five.
Russia registered Semax for medical use in December nineteen ninety-four. That gives it more than thirty years of medical history by twenty twenty-six.
Semax contains seven amino acids. Four come from a fragment of ACTH, a natural hormone. Three more complete the molecule.
In rats with interrupted brain blood flow, researchers found changes in genes linked to inflammation and nerve communication. Those findings suggest mechanisms, not clinical benefits in people.
A nineteen ninety-seven stroke report compared thirty given Semax plus care with eighty receiving conventional care. Its authors reported better neurological recovery. The English abstract does not specify randomization or blinding.
Stroke recovery and improving focus in healthy people are different questions. The preparation, population, and outcome matter.
The FDA's twenty twenty-six compounding review raised concerns about product characterization, impurities, and possible immune reactions.
A long history is part of the story. Careful human testing helps establish what the evidence supports.
World Peptide Foundation. Peptides in 2. Every experience matters.
